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Introduction
Frontotemporal dementia (FTD) is a term encompassing a variety of clinical syndromes which collectively are characterised by dysfunction, atrophy and/or hypometabolism of the frontal and temporal lobes. The neurodegeneration underlying FTD results from heterogeneous molecular pathologies, unified under the umbrella pathological term "frontotemporal lobar degeneration" (FTLD). This article will review the progress made in the field of FTD over the last few years, such as the publication of new consensus diagnostic criteria and the identification of new pathogenic mutations. Preclinical studies of FTD, such as the recent work on novel mouse models of FTD, will not be covered in this review.
Nosology and diagnosis
The previous 1998 Neary et al. criteria [1] described three syndromic variants associated with FTLD (frontotemporal dementia, progressive non-fluent aphasia and semantic dementia). By comparison, the current clinical classifications which divide FTD into two main syndromes: behavioural variant frontotemporal dementia (bvFTD) and primary progressive aphasia (PPA), with the latter further divided into subtypes on the basis of differences in the nature of the speech and language disorder [2] . In addition to these revised classifications, the clinical diagnostic categorisation has expanded to encompass the idea of an overlap syndrome between FTD and amyotrophic lateral sclerosis (ALS), given the identification of shared pathogenic mutations [3, 4] , ALS-type motor abnormalities in 14% of FTD patients [5] , and symptoms of FTD in 15-18% of ALS patients [6] .
FTD has long been considered primarily a young onset dementia. However, this has recently been cast into question, with 48% of FTD patients found to be aged 65 years or older at presentation [8] .
The underlying FTLD pathology can be divided into three main groups based on the predominant intracellular protein aggregate: FTLD-tau, FLTD-TDP and FTLD-FUS [7] . In addition to FTD these pathologies are also found to underlie corticobasal syndrome and progressive supranuclear palsy. The clinicopathological correlation between FTD and FTLD is variable; for example, there is a correlation between FTD with ALS and FTLD-TDP, and between semantic variant PPA and FTLD-TDP, whereas by comparison bvFTD does not correlate with any particular neuropathological subtype [7] . Certain pathogenic mutations are also associated with particular pathologies, notably between MAPT mutations and FTLD-tau pathology, and between C9orf72 hexanucleotide repeat expansions and FTLD-TDP pathology (see section 4 for more details).
Behavioural variant FTD (bvFTD)
The 2011 revised international consensus criteria for bvFTD [9] classify the disease as possible bvFTD (as diagnosed on the basis of behavioural and cognitive symptoms supported by neuropsychological findings), probable bvFTD (possible bvFTD AND functional decline and imaging changes in the form of frontal and/or anterior temporal lobe atrophy/hypometabolism/hypoperfusion), or definite bvFTD (possible or probable FTD AND either histopathological evidence of FTLD or a confirmed pathogenic mutation). These criteria are outlined in full in Table 1 (below): 
Exclusionary criteria for bvFTD
The following must be negative for any bvFTD diagnosis:
Pattern of deficits is better accounted for by other non-degenerative nervous system or medical disorders Behavioural disturbance is better accounted for by a psychiatric diagnosis
The following can be positive for possible bvFTD but must be negative for probable bvFTD:
Biomarkers strongly indicative of Alzheimer's disease or other neurodegenerative process *Early refers to symptom presentation within the first 3 years
The validity of these new bvFTD criteria has been assessed with a clinicopathological brain bank-based study of diagnostic sensitivity. Of 137 pathologically confirmed cases, 86% met criteria for possible bvFTD and 76% for probable bvFTD, representing a significant improvement in sensitivity compared to previous criteria [9] . A subsequent retrospective series looking at presenting features of pathologically confirmed cases found high sensitivity and specificity (possible FTD: sensitivity 95% for specificity 92%; probable FTD: sensitivity 85% for specificity 95%) [10] .
Despite these revised criteria, accurate clinical diagnosis of bvFTD can remain challenging and can be hard to distinguish from two particular disorders on clinical grounds alone. The first of these is "bvFTD phenocopy syndrome" [11] . Patients with this syndrome exhibit the clinical features of bvFTD (and would thus fulfil criteria for the diagnosis of possible bvFTD) but fail to show progressive functional decline, neuroimaging changes or neuropathological changes consistent with FTLD, and have a much better prognosis. The cause of bvFTD phenocopy syndrome is unclear, but this is likely to be heterogeneous and in some instances may be representative of a decompensated personality disorder or subclinical autism spectrum disorder [11] . However, comprehensive neuropsychiatric and neuropsychological profiling may help differentiate bvFTD and bvFTD phenocopy syndrome and the need for caution in attributing the latter diagnosis is underscored by the observation that two (related) cases diagnosed independently with phenocopy syndrome were found to tested positive for c9orf72 [12] .
The second diagnosis that can be confused with bvFTD is "frontal" or "behavioural/dysexecutive" variant of Alzheimer's disease (AD), representing one of three non-amnestic variants of AD specified in the updated AD diagnostic criteria [13] . In contrast to the typical AD presentation with memory impairment, the cognitive impairment in this instance is manifest primarily as impaired reasoning, judgment, and problem solving. The difficulty of distinguishing clinically between bvFTD and behavioural/dysexecutive variant AD is illustrated by a study showing that 52% of patients with pathologically-or biomarker-confirmed AD who presented with a behavioural or dysexecutive-predominant presentation met current criteria for possible bvFTD [14] . However, despite clinical similarities, these patients have different patterns of atrophy to bvFTD patients, with marked bilateral temporoparietal atrophy and limited frontal lobe atrophy [14] .
Primary progessive aphasia (PPA)
PPA is characterised by the progressive impairment of speech production, naming, syntax and/or word comprehension with initial relative preservation of other cognitive functions, and current diagnostic criteria are based on those described by Mesulam [15] . In 2011, consensus diagnostic criteria for PPA subtypes were published for the first time and these divide PPA into three groups: semantic variant PPA (svPPA), nonfluent variant PPA (nfvPPA) and logopenic variant PPA (lvPPA) [2] . When compared with the FTD syndromic variants described in the 1998 Neary et al. criteria [1] , svPPA and nfvPPA are considered to be broadly analogous to "semantic dementia" and "progressive non-fluent aphasia". However this concordance is not exact, as exemplified by a retrospective case series which found 51% of cases previously diagnosed as progressive non-fluent aphasia were reclassified as lvPPA rather than nfvPPA [16] . Research into clinicopathological correlations has found that the most common pathology in patients clinically diagnosed with lvPPA was AD [16, 17] and lvPPA is now considered an AD, rather than FTD, subtype. 
Definite pathology Clinical diagnosis plus one of:
Histopathological evidence of a specific neurodegenerative pathology (e.g. FTLD-tau, FTLD-TDP, AD, other)
Presence of a known pathogenic mutation Some questions persist about the ability of these proposed PPA subtypes to encompass all presentations with progressive aphasia, with Sajjadi et al. [18] noting that 41% of 46 patients with PPA did not meet diagnostic criteria for any of the three PPA subtypes.
"Right temporal" FTD
One anatomical variant of FTD not fully captured by the reformulated bvFTD and PPA clinical classifications is that in which pathology predominantly affects the right temporal lobe. This has been variously described as "right temporal variant FTD" [19, 20] and "right temporal lobe atrophy" [21] . Two clinical subtypes of "right temporal FTD" have been described to date. Patients with "right temporal" bvFTD typically present with behavioural disorders and personality change, with additional frontal lobe atrophy. In these cases tau is the predominant pathology. By comparison, patients with "right temporal" semantic dementia [sic] exhibit topographical disorientation, prosopagnosia and impaired word comprehension, with minimal frontal lobe atrophy and TDP-43 as the main underlying pathology [22] .
Cognition
Outside of the dysexecutive syndrome and the disruption of speech and language that are central to the cognitive profiles of bvFTD and PPA respectively, significant recent attention has been devoted to the nature of memory deficits in these disorders. Episodic memory is considered to be relatively preserved in bvFTD (and in fact is one of the diagnostic criteria) but there is evidence to suggest that it is similarly impaired in both AD and bvFTD [23] , possibly as a result of anterior hippocampal involvement in bvFTD, and that the previously reported preservation of episodic memory may reflect in part the incorrect inclusion of patients with bvFTD phenocopy [24] . By comparison, allocentric spatial memory and spatial orientation are relatively preserved in bvFTD but impaired in AD [25, 26] , likely reflecting the sparing of the precuneus and posterior hippocampus in bvFTD, and this information may help in the differential diagnosis of these disorders.
Emerging information on the initial cognitive changes in FTD are being obtained from the GENFI study (GENetic FTD Initiative) which has shown impairment on tests of executive function and naming five years prior to anticipated symptom onset [27] .
Imaging
FTD variants are characterised by imaging changes affecting the frontal and/or temporal lobes in the form of atrophy, hypometabolism and hypoperfusion and such imaging abnormalities are listed within the diagnostic criteria for both bvFTD and PPA. In familial FTD, the onset of atrophy significantly predates symptoms, with mutation carriers found to have significant reduction in insular and temporal lobe volume 10 years prior to anticipated symptom onset [27] . Much of the more recent imaging research in FTD has focused on determination of changes in brain structural and functional connectivity. Diffusion tensor imaging has shown progressive disruption of white matter tracts in all FTD subtypes [28, 29] , with reduced tract integrity correlating with symptom progression [30] . The observation that white matter pathways are impaired in presymptomatic mutation carriers indicates that disruption of structural connectivity is an early feature of FTD [31, 32] .
Resting state ("task-free") functional MRI studies have found that FTD syndromes are associated with disruption of different functional brain networks [33] . In bvFTD there is reduced functional connectivity within the frontal lobe-predominant network considered to underpin emotional salience [34, 35] . Changes in nonfluent variant PPA are found within a predominantly left-hemisphere network encompassing the frontal operculum, supplementary motor cortex and inferior parietal lobule, consistent with the complementary roles of these brain regions in the generation of fluent speech, whereas the functional brain network implicated in semantic variant PPA involves the temporal poles, ventral striatum and amygdala [33] .
CSF biomarkers
Testing of CSF is not currently used in routine clinical practice to diagnose FTD although analysis of CSF AD biomarkers (Aβ and tau) can help differentiate AD from FTD, with CSF Aβ 1-42 associated with a sensitivity of 77% for diagnosing AD against FTD for a specificity of 95% [36] .
CSF neurofilament light chain (NfL) levels may represent a possible future biomarker of FTD. These have been found to be significantly higher in FTD than AD or controls and levels correlate with performance on neuropsychological tests and with frontal/temporal atrophy [37] , although their sensitivity and specificity remain to be determined. NfL levels have recently been shown to distinguish ALS and controls with a high level of sensitivity and specificity and to be a strong independent predictor of survival [38] , and this may have relevance for FTD given the neuropathological overlap between ALS and FTD.
Genetics and molecular pathology
Approximately 40% of FTD patients have a positive family history of disease [39] , and 10-25% of family pedigrees are associated with an autosomal dominant pattern of inheritance [40, 41] . The commonest pathogenic mutations in FTD affect the C9orf72, MAPT and GRN genes, which together account for 10-20% of all FTD cases [42] .
Arguably the most important recent advance in the field of FTD genetics is the discovery that an abnormal expansion of a hexanucleotide repeat in the C9orf72 gene accounts for 25% of familial and 6% of sporadic FTD cases [43] [44] [45] and also accounts for 30-50% and 5-7% of familial and sporadic ALS respectively [44] . Other less frequent mutations common to both FTD and ALS have been found, such as mutations in he VCP and CHCHD10 genes (see Table 3 ). TDP-43 positive inclusions are found in the CNS of patients with both ALS and FTD [46] . [4] . This is exemplified by the presence of the TMEM106B rs1990622 major allele which, in FTD patients with C9orf72 mutations, correlates with later age of disease onset and later age of death [47] .
Treatments and current trials
There are no disease-modifying treatments for FTD and the mainstay of management remains non-pharmacological care [48] . However, a small open-label study using citalopram to treat behavioural disturbance did find a significant improvement on measures of disinhibition, irritability and depression [49] .
A phase III study of a tau aggregation inhibitor is currently under way and is expected to report results in 2016 [50] .
Conclusions
There have been significant recent advances in understanding the FTD syndromes and these are reflected in the publication of new diagnostic criteria for bvFTD and PPA subtypes. While an improvement on previous criteria, these remain work in progress and future studies will undoubtedly seek to address the current outstanding diagnostic challenges outlined in this review article. Ongoing and future work into molecular genetics and neuroimaging will aid in the phenotyping of FTD, and the planned further study of presymptomatic mutation carriers, within programmes such as GENFI2, will hopefully deliver new biomarkers of early disease.
Sadly, progress in developing disease-modifying drugs for the treatment of FTD remains slow. However, these advances in clinical understanding, when combined with developments in systems biology research into disease mechanisms, will provide a more robust framework for experimental medicine and, from there, the delivery of effective treatments for FTD.
